Showing results (381-390 of 4,241) with videos related to
Sort By:
Pageof 425
Journal for Immunotherapy of Cancer|April 10, 2025
Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphomaCharlotte Junkuhn, Phillip Schiele, Anna Luzie Walter, et al.Journal for Immunotherapy of Cancer|April 10, 2025
Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanomaQian Sun, Nina Wang, Juliane Poelchen, et al.Journal for Immunotherapy of Cancer|April 8, 2025
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trialMeiting Chen, Riqing Huang, Qixiang Rong, et al.Journal for Immunotherapy of Cancer|April 17, 2025
Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapyEnoch Tin, Ismat Khatri, Karen Fang, et al.Journal for Immunotherapy of Cancer|April 17, 2025
Past failures and new horizons: the nuances of tertiary lymphoid structures in high-grade serous ovarian cancer may contribute to immunotherapy effectivenessRufiaat Rashid, Lan Coffman, Tullia C Bruno, et al.Journal for Immunotherapy of Cancer|April 15, 2025
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancerZhi-Yu Xia, Jia-Cheng Xiang, Jin-Zhou Xu, et al.Journal for Immunotherapy of Cancer|April 15, 2025
METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulationYonghua Tong, Zhiqiang Chen, Jian Wu, et al.Journal for Immunotherapy of Cancer|April 5, 2025
Characteristics of second primary malignancies following bispecific antibodies therapyXiaojie Liang, Baiwei Luo, Bingyu Lin, et al.Journal for Immunotherapy of Cancer|April 5, 2025
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigensJames William Jenkins, Alvaro Peña, Sarah A Castro, et al.Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.Pageof 425